ArticleMikrochimica acta2026
Thermo-alkaline-activated ZrFe-MOF interface for ultrasensitive electrochemical MiRNA biosensing.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
We developed a highly sensitive electrochemical sensor based on zirconium-iron metal-organic frameworks (ZrFe-MOF) for the precise detection of ultra-low abundance miRNA-21. The construction of this sensor, through an innovative thermal alkaline activation strategy, exposed abundant binding sites on the surface of ZrFe-MOF, significantly improving aptamer (Apt) loading efficiency, thereby, achieving unprecedented sensitivity with a wide linear range (100 aM-10 nM, R² = 0.997) and a record-low detection limit of 19.33 aM - outperforming existing methods by 1-2 orders of magnitude. Besides, the biosensor successfully discriminates miRNA-21 expression profiles in breast cancer cell lines and breast adenocarcinoma (MDA-MB-231 vs. MCF-7 vs. MCF-10 A), showing high consistency with qPCR results. This work not only demonstrates a novel binding-site engineering strategy for nucleic acid detection but also presents a clinically viable platform for early cancer diagnosis with superior sensitivity, specificity, and reproducibility. This thermal-alkaline activation strategy could be extended to other bimetallic MOFs for multiplex miRNA detection, with future efforts targeting sensor miniaturization for point-of-care use. Current challenges include balancing the material's electron transfer efficiency with long-term storage stability and verifying the sensor's performance in large-scale clinical cohort samples.
Indexed as
Identifiers
41498981What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.